Swiss National Bank Purchases 8,000 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Swiss National Bank increased its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Rating) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 176,900 shares of the medical technology company’s stock after acquiring an additional 8,000 shares during the quarter. Swiss National Bank owned about 0.17% of Alphatec worth $2,185,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Great West Life Assurance Co. Can purchased a new position in shares of Alphatec during the 3rd quarter valued at approximately $28,000. Point72 Hong Kong Ltd purchased a new stake in shares of Alphatec during the 2nd quarter worth about $46,000. Quantbot Technologies LP acquired a new stake in shares of Alphatec during the 3rd quarter valued at about $59,000. Tower Research Capital LLC TRC increased its stake in shares of Alphatec by 66.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 7,621 shares of the medical technology company’s stock valued at $67,000 after purchasing an additional 3,055 shares in the last quarter. Finally, Birchview Capital LP acquired a new position in Alphatec in the 3rd quarter worth about $87,000. Hedge funds and other institutional investors own 48.59% of the company’s stock.

Insider Buying and Selling

In other Alphatec news, CEO Patrick Miles sold 60,000 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $15.82, for a total value of $949,200.00. Following the completion of the sale, the chief executive officer now directly owns 5,868,117 shares in the company, valued at approximately $92,833,610.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Alphatec news, CEO Patrick Miles sold 60,000 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $15.82, for a total value of $949,200.00. Following the transaction, the chief executive officer now directly owns 5,868,117 shares in the company, valued at approximately $92,833,610.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John Todd Koning sold 16,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 20th. The stock was sold at an average price of $16.42, for a total transaction of $270,930.00. Following the sale, the chief financial officer now owns 415,552 shares of the company’s stock, valued at approximately $6,823,363.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,134,192 shares of company stock worth $991,909,317. 33.93% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on ATEC shares. Morgan Stanley raised their price objective on Alphatec from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, March 1st. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Wednesday, March 1st. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Alphatec in a research report on Monday, April 17th. Finally, StockNews.com assumed coverage on shares of Alphatec in a research report on Thursday, May 18th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.25.

Alphatec Stock Down 1.9 %

Shares of NASDAQ ATEC opened at $14.74 on Friday. The firm has a 50-day simple moving average of $15.41 and a 200-day simple moving average of $13.39. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -10.24 and a beta of 1.25. Alphatec Holdings, Inc. has a 52 week low of $5.73 and a 52 week high of $17.13.

Alphatec (NASDAQ:ATEC – Get Rating) last released its quarterly earnings data on Tuesday, February 28th. The medical technology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Alphatec had a negative net margin of 39.28% and a negative return on equity of 575.45%. The business had revenue of $105.94 million during the quarter, compared to analyst estimates of $105.70 million. As a group, equities research analysts expect that Alphatec Holdings, Inc. will post -1.21 EPS for the current year.

Alphatec Company Profile

(Get Rating)

Alphatec Holdings, Inc engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.